New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSemaglutide vs Larazotide Acetate

Semaglutide vs Larazotide Acetate

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Semaglutide
Recovery & Repair
Larazotide Acetate
Summary
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
Half-Life
~7 days
Local gut action; minimal systemic exposure
Admin Route
SubQ, Oral
Oral
Research
Typical Dose
0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
0.5-2 mg
Frequency
Once weekly, subcutaneous
3x daily
Key Benefits
  • Average 15–20% body weight reduction in clinical trials (STEP trials)
  • Significant reduction in appetite and food cravings
  • Improvement in blood sugar control and insulin sensitivity
  • Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
  • May reduce risk of kidney disease
  • Improves metabolic markers (cholesterol, blood pressure)
  • FDA-approved — extensively studied with robust safety data
  • Weekly dosing convenience
  • Directly reduces intestinal tight junction permeability
  • Clinical efficacy in celiac disease (Phase 3 trials)
  • Reduces systemic inflammation from gut permeability
  • Targets root cause of leaky gut (Zonulin pathway)
  • Local gut action without systemic absorption
  • Potential application in IBS, IBD, autoimmune conditions
Side Effects
  • Nausea (most common, especially during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal discomfort
  • +4 more
  • Headache (mild, dose-dependent)
  • Nausea (rare)
  • Well-tolerated overall in clinical trials
Stacks With